Immunocore Holdings plc – NASDAQ:IMCR

Add to watchlist

$32.34

+3.16

+10.83%

Market closed

Open in 21 minutes

-26.15%

month

-26.15%

quarter

-58.01%

year

Market Cap	1.41B
Enterprise value	2.11B

P/E	-44.31
EV/Sales	14.68
EV/EBITDA	-66.55
Price/Sales	12.05
Price/Book	6.21
PEG ratio	-0.62
EPS	-1.28

Revenue	275.38M
EBITDA	-35.27M
Income	-63.02M
Revenue Q/Q	58.28%
Revenue Y/Y	66.09%

Profit margin	-28.68%
Oper. margin	-27.56%
Gross margin	99.68%
EBIT margin	-27.56%
EBITDA margin	-12.81%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Immunocore Holdings Stock Forecast

M Q Y

Last Year

$70.2

Potential upside: 117.06%

Analysts Price target
Financials & Ratios estimates

Immunocore Holdings plc (NASDAQ:IMCR): Profit margin
Jun 2023	47.76M	-14.07M	-29.47%
Sep 2023	51.48M	1.90M	3.7%
Dec 2023	105.63M	-26.41M	-25.01%
Mar 2024	70.50M	-24.43M	-34.66%

Immunocore Holdings plc (NASDAQ:IMCR): Debt to assets
Jun 2023	440360000	163.08M	37.03%
Sep 2023	464119000	172.57M	37.18%
Dec 2023	597001000	228.15M	38.22%
Mar 2024	993987000	634.45M	63.83%

Immunocore Holdings plc (NASDAQ:IMCR): Cash Flow
Jun 2023	-2.39M	2.70M	7.35M
Sep 2023	5.11M	2.14M	6.41M
Dec 2023	-8.57M	-9.87M	18.08M
Mar 2024	-4.58M	-430K	396.01M

Immunocore Holdings alternative data

Immunocore Holdings plc (NASDAQ:IMCR): Employee count
Aug 2023	408
Sep 2023	408
Oct 2023	408
Nov 2023	408
Dec 2023	408
Jan 2024	408
Feb 2024	408
Mar 2024	497
Apr 2024	497
May 2024	497
Jun 2024	497
Jul 2024	497

Immunocore Holdings
Hedge Funds Holdings Q1 2023

36.88% -21.99%

of IMCR is owned by hedge funds

60 -44

hedge funds hold IMCR stock

16.86M -13.42M

shares is hold by hedge funds

IMCR hedge funds holdings changes

Immunocore Holdings
Insider Trading

Immunocore Holdings plc (NASDAQ:IMCR): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	4375
Feb 2024	0	120000
Apr 2024	0	4375

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	1 Apr 2024	ST LEGER TINA AMBER officer: CHIEF HR OFFICER officer: CHIEF HR OFFICER	Employee Share Option (Right to Buy)	4,375	$29.87	$130,681
Option	1 Apr 2024	ST LEGER TINA AMBER officer: CHIEF HR OFFICER officer: CHIEF HR OFFICER	Ordinary Shares	4,375	$29.87	$130,681
Sale	1 Apr 2024	ST LEGER TINA AMBER officer: CHIEF HR OFFICER officer: CHIEF HR OFFICER	Ordinary Shares	4,375	$64.06	$280,263
Option	28 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Employee Share Option (Right to Buy)	36,509	$17.46	$637,447
Option	28 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Ordinary Shares	36,509	$17.46	$637,447
Sale	28 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Ordinary Shares	16,900	$67.61	$1,142,609
Sale	28 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Ordinary Shares	7,472	$68.84	$514,372
Sale	28 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Ordinary Shares	10,937	$69.73	$762,637
Sale	28 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Ordinary Shares	1,200	$70.45	$84,540
Option	27 Feb 2024	BERMAN DAVID M officer: HEAD OF R&D officer: HEAD OF R&D	Employee Share Option (Right to Buy)	54,938	$17.46	$959,217

IMCR insider trading transactions

Immunocore Holdings
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript
Q4 2022 1 Mar 2023	Q4 2022 Earnings Call Transcript
Q2 2022 10 Aug 2022	Q2 2022 Earnings Call Transcript

IMCR earnings call transcripts

Immunocore Holdings
Latest News

Thursday, 26 December 2024
14:10	3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025	zacks.com
Monday, 23 December 2024
08:50	Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term	zacks.com
07:00	Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME	globenewswire.com
Friday, 13 December 2024
14:10	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?	benzinga.com
Thursday, 12 December 2024
13:06	All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy	zacks.com
07:21	New Strong Buy Stocks for December 12th	zacks.com
Tuesday, 3 December 2024
01:00	Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma	globenewswire.com
Thursday, 28 November 2024
11:01	Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?	zacks.com
Tuesday, 26 November 2024
07:26	New Strong Buy Stocks for November 26th	zacks.com
Monday, 11 November 2024
07:16	3 Fast-Growing Stocks Analysts See Doubling in Price	marketbeat.com
Friday, 8 November 2024
10:55	Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know	zacks.com
07:00	Immunocore to present at upcoming investor conferences	globenewswire.com
Wednesday, 6 November 2024
07:00	Immunocore reports third quarter financial results and provides a business update	globenewswire.com
Tuesday, 5 November 2024
13:00	Immunocore (IMCR) Upgraded to Buy: Here's Why	zacks.com
Saturday, 14 September 2024
03:00	Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer	globenewswire.com
Thursday, 12 September 2024
16:05	Immunocore to present at the 2024 Cantor Global Healthcare Conference	globenewswire.com
Friday, 30 August 2024
11:40	Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak	seekingalpha.com
Monday, 12 August 2024
04:12	Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal	seekingalpha.com
Sunday, 11 August 2024
06:53	Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 6 August 2024
10:41	3 Small-Cap Stocks with Significant Growth Potential	investorplace.com
Saturday, 1 June 2024
08:00	Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	globenewswire.com
Friday, 31 May 2024
16:05	Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024	globenewswire.com
Thursday, 30 May 2024
16:00	Immunocore to present at the Jefferies Global Healthcare Conference	globenewswire.com
Wednesday, 29 May 2024
07:00	Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma	globenewswire.com
Friday, 24 May 2024
12:00	Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.	barrons.com
Wednesday, 8 May 2024
07:00	Immunocore reports first quarter financial results and provides a business update	globenewswire.com
Wednesday, 24 April 2024
10:00	Immunocore announces upcoming presentation and posters at ASCO 2024	globenewswire.com
Thursday, 4 April 2024
16:00	Immunocore to present at upcoming investor conferences	GlobeNewsWire
Friday, 1 March 2024
07:00	Immunocore to present at upcoming investor conferences	GlobeNewsWire
Wednesday, 21 February 2024
07:00	Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 12 Jun 2025

Delcath Systems: Growing Fast, But Business Model Is Fragile
Seeking Alpha 17 Nov 2023

Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Seeking Alpha 1 Nov 2023

Immunocore: First Half Of 2024 IMC-F106C Data Expected
Seeking Alpha 27 Aug 2023

Immunocore: KIMMTRAK Adoption Continues At Rapid Pace, Expanding To New Markets, Reiterate Buy
Seeking Alpha 14 Aug 2023

August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February
Seeking Alpha 31 Jul 2023

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge
Seeking Alpha 16 Apr 2023

April MDA Breakout Stocks/ETFs Week 16 - 2023: High-Frequency Gainers To Give You An Edge
Seeking Alpha 27 Feb 2023

Immunocore Holdings: A Meteoric Rise Likely Here To Stay
Seeking Alpha 23 Dec 2022

Immunocore: Potential To Unlock Capital With New Melanoma Treatment Paradigm
Seeking Alpha 5 Oct 2022

Immunocore: Attractive Commercial-Stage Biopharma

Frequently Asked Questions (FAQ)

What's the price of Immunocore Holdings stock today?

One share of Immunocore Holdings stock can currently be purchased for approximately $32.34.
When is Immunocore Holdings's next earnings date?

Unfortunately, Immunocore Holdings's (IMCR) next earnings date is currently unknown.
Does Immunocore Holdings pay dividends?

No, Immunocore Holdings does not pay dividends.
How much money does Immunocore Holdings make?

Immunocore Holdings has a market capitalization of 1.41B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 73.53% to 249.43M US dollars.
What is Immunocore Holdings's stock symbol?

Immunocore Holdings plc is traded on the NASDAQ under the ticker symbol "IMCR".
What is Immunocore Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Immunocore Holdings?

Shares of Immunocore Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Immunocore Holdings have?

As Jul 2024, Immunocore Holdings employs 497 workers.
When Immunocore Holdings went public?

Immunocore Holdings plc is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
What is Immunocore Holdings's official website?

The official website for Immunocore Holdings is immunocore.com.
How can i contact Immunocore Holdings?

Immunocore Holdings can be reached via phone at +44 1235 438600.
What is Immunocore Holdings stock forecast & price target?

Based on 5 Wall Street analysts` predicted price targets for Immunocore Holdings in the last 12 months, the avarage price target is $70.2. The average price target represents a 117.06% change from the last price of $32.34.

Immunocore Holdings plc

immunocore.com

Exchange:

NASDAQ

Full time employees:

497

Industry:

Biotechnology

Sector:

Healthcare

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

+44 1235 438600

92 Park Drive
Abingdon, OX14 4RY

CIK: 0001671927
ISIN: US45258D1054
CUSIP: 45258D105